Effect of Renal Impairment on the Pharmacokinetics, and Safety of Megestrol Acetate Concentrated Suspension

NCT ID: NCT00637403

Last Updated: 2016-10-17

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 7 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-05-31
• Study Completion Date: 2006-05-31

Brief Summary

To determine the pharmacokinetics and safety of megestrol acetate after a single oral 300 mg dose of megestrol acetate concentrated suspension in healthy subjects, and subjects with varying degrees of renal impairment

Conditions

Healthy

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Blinding Strategy: NONE

Study Groups

I

Megestrol acetate concentrated suspension in subjects with normal renal function

Group Type: ACTIVE_COMPARATOR

Megestrol acetate concentrated suspension 125 mg/mL

Intervention Type: DRUG

Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with normal renal function (CLcr \>80 mL/min)

II

Megestrol acetate concentrated suspension in subjects with mild renal impairment

Group Type: EXPERIMENTAL

Megestrol acetate concentrated suspension 125 mg/mL

Intervention Type: DRUG

Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with mild renal impairment (CLcr 50 - 80 mL/min)

III

Megestrol acetate concentrated suspension in subjects with moderate renal impairment

Group Type: EXPERIMENTAL

Megestrol acetate concentrated suspension 125 mg/mL

Intervention Type: DRUG

Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with moderate renal impairment (CLcr 30 - \<50 mL/min)

IV

Megestrol acetate concentrated suspension in subjects with severe renal impairment

Group Type: EXPERIMENTAL

Megestrol acetate concentrated suspension 125 mg/mL

Intervention Type: DRUG

Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with severe renal impairment (CLcr \<30 mL/min and not on hemodialysis)

V

Megestrol acetate concentrated suspension in subjects with end stage renal disease

Group Type: EXPERIMENTAL

Megestrol acetate concentrated suspension 125 mg/mL

Intervention Type: DRUG

Megestrol acetate concentrated suspension (125 mg/mL) administered orally as 2 single doses of 300 mg (2.4 mL x 125 mg/mL) each in subjects with end stage renal disease undergoing hemodialysis. Washout period of 21 days between each dose

Interventions

Megestrol acetate concentrated suspension 125 mg/mL

Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with normal renal function (CLcr \>80 mL/min)

Intervention Type: DRUG

Megestrol acetate concentrated suspension 125 mg/mL

Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with mild renal impairment (CLcr 50 - 80 mL/min)

Intervention Type: DRUG

Megestrol acetate concentrated suspension 125 mg/mL

Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with moderate renal impairment (CLcr 30 - \<50 mL/min)

Intervention Type: DRUG

Megestrol acetate concentrated suspension 125 mg/mL

Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with severe renal impairment (CLcr \<30 mL/min and not on hemodialysis)

Intervention Type: DRUG

Megestrol acetate concentrated suspension 125 mg/mL

Megestrol acetate concentrated suspension (125 mg/mL) administered orally as 2 single doses of 300 mg (2.4 mL x 125 mg/mL) each in subjects with end stage renal disease undergoing hemodialysis. Washout period of 21 days between each dose

Intervention Type: DRUG

Other Intervention Names

Megace ES; Megace ES; Megace ES; Megace ES; Megace ES

Eligibility Criteria

Inclusion Criteria

Healthy Subjects with Normal Renal Function

1. BMI ≥18 kg/m2 and ≤35 kg/m2

2. Females of child-bearing potential must use an adequate and reliable method of contraception. Postmenopausal females must be postmenopausal ≥1 year and have elevated serum FSH

3. Able to provide written informed consent

4. Normal renal function, defined as estimated creatinine clearance (CLcr) >80 mL/min at screening

Subjects with Mild, Moderate, or Severe Renal Impairment or ESRD

1. Renal impairment defined as creatinine clearance <80 mL/min as determined using the Cockroft-Gault formula. Subjects grouped according to degree of renal dysfunction: mild (CLcr = >50 and ≤80 mL/min), moderate (CLcr = >30 and ≤50 mL/min), or severe (CLcr = ≤30 mL/min)

2. Renal Impairment subjects must have evidence of stable renal impairment. Defined as having CLcr values within 25% of each other from 2 separately measured serum creatinine clearances using the Cockroft-Gault formula

3. ESRD subjects require hemodialysis for at least 3 months

4. Subjects with renal impairment or ESRD may have clinical laboratory test result deviations that are judged by the Investigator to be consistent with the renal condition of the subject or of no additional clinical significance for this study

5. Subjects with renal impairment or ESRD, must have stable underlying medical conditions for at least 90 days prior to the start of study participation

6. Renal impaired subjects may smoke up to 5 cigarettes per day

Exclusion Criteria

Healthy Subjects with Normal Renal Function

1. Clinically significant (history of or active) cardiac, hepatic, renal, pulmonary, endocrine, neurological, infectious, gastrointestinal, hematologic, oncologic, or psychiatric disease that could put the subject at increased risk or could interfere with the objectives of the study

2. Presence of any screening laboratory values outside the range of normal values and deemed clinically significant by the Investigator

3. Use of a prescription drug within 14 days of study start, a non-prescription drug within 7 days of study start, or need of concomitant medication during the study

4. Use of any drugs or herbal products known to inhibit or induce liver enzymes involved in drug metabolism (CYP P450) within 30 days prior to 1st dose

5. History of allergic reaction or serum sickness to any drug or drug metabolites

6. Whole blood donation within 56 days prior to the first MA-CS dose or plasma donation within 7 days prior to the first MA-CS dose

7. Positive test for HIV antibody or hepatitis B surface antigen (positive HIV or hepatitis C antibody for ESRD subjects are acceptable)

8. Presence of drugs of abuse and/or alcohol

9. Participation in another investigational drug study within 30 days prior to the first MA-CS dose

10. History of recent drug abuse or alcohol addiction during past 2 years

11. Pregnant or breastfeeding

12. Consumption of grapefruit containing foods and beverages within 7 days prior to the first MA-CS dose

13. History of recurrent thromboembolic events, a thromboembolic event in past three months, or those still receiving long-term anticoagulation for thromboembolism

Subjects with Mild, Moderate, or Severe Renal Impairment or ESRD

1. Unstable disease defined as concurrent medical conditions that change significantly within 90 days

2. Changes in concomitant medications within 14 days prior to first dose administration or expected changes during study participation

3. Subjects with a renal transplant

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Covance

INDUSTRY

Sponsor Role: collaborator

SFBC Anapharm

INDUSTRY

Sponsor Role: collaborator

Par Pharmaceutical, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Kenneth C Lasseter, MD

Role: PRINCIPAL_INVESTIGATOR

SFBC International

Lynn D. Kramer, MD

Role: STUDY_DIRECTOR

Par Pharmaceutical, Inc.

Locations

SFBC International

Miami, Florida, United States

Countries

United States

Other Identifiers

100.2.C.002

Identifier Type: -

Identifier Source: org_study_id